EMEA-002886-PIP02-23 - paediatric investigation plan

rocatinlimab

Key facts

• Active substance:
  rocatinlimab
• Therapeutic area:
  Skin and subcutaneous tissue disorders
• Decision number:
  P/0023/2024
• PIP number:
  EMEA-002886-PIP02-23
• Condition(s) / indication(s):
  Treatment of prurigo nodularis
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  01/02/2024
• Compliance check done:
  No

Decision

P/0023/2024 : EMA decision of 1 February 2024 on the granting of a product specific waiver for rocatinlimab (EMEA-002886-PIP02-23)

Adopted Reference Number: EMA/27712/2024